Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders

Jurjen J. Luykx, Johannes A. Carpay

Research output: Contribution to journalReview articleAcademicpeer-review

9 Citations (Scopus)

Abstract

Importance of the field: Nervous system adverse drug reactions (NS-ADRs), such as cognitive complaints and paresthesia, are among the most frequent and clinically important ADRs of topiramate. Studying ADR profiles across disorders is clinically relevant because treatment decision-making in neuropsychiatry is highly guided by ADR profiles. Areas covered in this review: We used medline searches (until July 2009) to review the NS-ADRs of topiramate across the most investigated topiramate indications: alcohol dependence, essential tremor, binge-eating disorder, bulimia nervosa, migraine and epilepsy. We compared NS-ADRs between these disorders but did not carry out meta-analysis. What the reader will gain: ADR profiles greatly differed between disorders. Drop-outs due to ADRs highly varied between disorders: from 2% in the bulimia nervosa group to 29% in the migraine group. Paresthesia was the most common NS-ADR for all disorders but frequencies also differed between disorders. Cognitive complaints were frequent and were reported in comparable proportions. Take home message: When prescribing topiramate in neuropsychiatry, physicians should be aware that NS-ADR profiles have been found to differ between disorders. Differences in drop-out rates due to ADRs and in frequencies of specific NS-ADRs across disorders must be taken into account when evaluating the potential harm of topiramate in clinical practice.

Original languageEnglish
Pages (from-to)623-631
Number of pages9
JournalExpert opinion on drug safety
Volume9
Issue number4
DOIs
Publication statusPublished - Jul 2010
Externally publishedYes

Keywords

  • Side effect(s)
  • adverse effect(s)
  • neuromodulatory drug(s)
  • neuropsychiatry
  • topiramate

Cite this